These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10477917)

  • 1. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
    Cohen-Jonathan E; Toulas C; Ader I; Monteil S; Allal C; Bonnet J; Hamilton AD; Sebti SM; Daly-Schveitzer N; Favre G
    Radiat Res; 1999 Oct; 152(4):404-11. PubMed ID: 10477917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
    Ader I; Toulas C; Dalenc F; Delmas C; Bonnet J; Cohen-Jonathan E; Favre G
    Oncogene; 2002 Sep; 21(39):5998-6006. PubMed ID: 12203112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
    Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells.
    Cohen-Jonathan E; Toulas C; Monteil S; Couderc B; Maret A; Bard JJ; Prats H; Daly-Schveitzer N; Favre G
    Cancer Res; 1997 Apr; 57(7):1364-70. PubMed ID: 9102225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
    Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B; Prendergast GC; Fenton RG
    Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
    Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
    Cohen-Jonathan E; Evans SM; Koch CJ; Muschel RJ; McKenna WG; Wu J; Bernhard EJ
    Cancer Res; 2001 Mar; 61(5):2289-93. PubMed ID: 11280800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
    Wesierska-Gadek J; Kramer MP; Schmid G
    J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J; Schweizer P; Girgert R
    Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
    Kim J; Seong J; Kim SH
    Ann N Y Acad Sci; 2004 Dec; 1030():95-102. PubMed ID: 15659785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.